Crisaborole

Eucrisa, Staquis (crisaborole) is a small molecule pharmaceutical. Crisaborole was first approved as Eucrisa on 2016-12-14. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat atopic dermatitis. It is known to target cAMP-specific 3',5'-cyclic phosphodiesterase 4B, high affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A, and calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A. Eucrisa's patents are valid until 2030-01-20 (FDA).